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Rationale: Docosahexaenoic acid (DHA) in cell membrane may influence breast cancer
(BC) patients’ prognosis, affecting tumor cells sensitivity to chemo- and radio-therapy
and likely modulating inflammation. The possibility of identifying BC patients presenting
with low DHA levels and/or low ability of DHA incorporation into cell membrane might
help to treat this condition.
Methods: We enrolled BC patients and healthy controls, recording their seafood dietary
intake. DHA in form of algal oil was administered for 10 consecutive days (2 g/day).
Blood samples were collected at baseline (T0) and after 10 days of supplementation
(T1) to assess DHA, omega-3 index, as the sum of DHA + eicosapentaenoic acid
(EPA), in red blood cells (RBC) membranes and plasma tumor necrosis factor-alpha and
interleukin-6 levels. Pre- and post-treatment fatty acid profiles were obtained by gas-
chromatography. Parametric and non-parametric tests were performed, as appropriate,
and P-value < 0.05 was considered statistically significant.
Results: Forty-three women were studied, divided into 4 groups: 11 patients with
BRCA1/2 gene mutation (M group), 12 patients with familiar positive history for BC
(F group), 10 patients with sporadic BC (S group), and 10 healthy controls (C group).
DHA and omega-3 index increased from T0 to T1 in the 3 groups of BC patients
and in controls (P < 0.001). No difference was found in DHA incorporation between
each group of BC patients and between patients and controls, except for M group,
which incorporated higher DHA levels with respect to controls (β = 0.42; P = 0.03).
No association was documented between cytokines levels and DHA and omega-
3 index at baseline and after DHA supplementation. Independent of the presence
of BC, women considered as “good seafood consumers” showed at baseline DHA
and omega-3 index higher with respect to “low seafood consumers” (P = 0.04;
P = 0.007, respectively). After supplementation, the increase in DHA levels was greater
in “low seafood consumers” with respect to “good seafood consumers” (P < 0.0001).
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Conclusion: DHA supplementation was associated with increased DHA levels and
omega-3 index in RBC membranes of BC cancer patients, independent of the type of
BC presentation, and in controls. BRCA1/2 mutation, as well as low seafood consuming
habits in both BC patients and healthy controls, seem to be associated with greater
ability of DHA incorporation. Larger samples of BC patients are necessary to confirm our
observation.
Keywords: breast cancer, DHA, omega-3 index, omega-3 fatty acids, BRCA
INTRODUCTION
Breast cancer (BC) is the most common cancer in women,
with an incidence greater than 1 million of new cases per year
worldwide (Bougnoux et al., 2009, 2010). A strong relationship
exists between diet, overweight and risk of primary BC and its
recurrence (Amadou et al., 2013; Molfino et al., 2016). Diets
with a high content in omega-6 polyunsaturated fatty acids
(PUFAs), and relatively low omega-3 PUFAs (Molfino et al.,
2014), are associated with increased risk to develop BC and its
relapse (Chlebowski et al., 2006; de Lorgeril and Salen, 2012;
Laviano et al., 2013). Moreover, omega-3 PUFAs, in particular the
docosahexaenoic acid (DHA), are able to influence the efficacy
of chemo- and radio- therapy in BC patients (Bougnoux et al.,
2009, 2010), sensitizing the malignant tumor cells to chemo-
and radio-therapy, not increasing the toxicity on non-tumor
tissues (Bougnoux et al., 2010; Hajjaji et al., 2011; Laviano et al.,
2012). The lipid environment of cancer cells (i.e., the lipid
component of cell membranes) may influence tumor sensitivity
to chemotherapeutic agents. The membrane lipids of cancer
cells are similar to those of storage lipids in terms of fatty
acids composition, suggesting that DHA levels may potentially
influence the activity of anti-tumor agents (Bougnoux et al.,
1999, 2010). The dietary supplementation with DHA might be
able to increase the effectiveness of systemic chemotherapy and
local mammary irradiation. In particular, DHA from food or
from exogenous supplementation, after intestinal absorption,
is rapidly incorporated into circulating phospholipids and in
those of cell membranes, including the red blood cells (RBC).
A study showed that in BC patients the incorporation of
DHA in circulating phospholipids is variable, and two different
phenotypes of BC patients were identified: “high-incorporator”
(with high incorporation of DHA in phospholipids) and “low-
incorporator” (with poor or reduced incorporation of DHA
in phospholipids) (Bougnoux et al., 2009). The possibility of
recognizing “low-incorporator” patients would identify patients
who might significantly increase the intake of DHA to increase
the sensitivity of the tumor to cancer therapies. In addition,
it could be also hypothesized that “low-incorporators” may
have an increased susceptibility to develop BC or a tumor
recurrence.
Studies have been conducted on a possible relationship
between PUFAs metabolism and the pathways involving the
Breast Related Cancer Antigens (BRCA) 1 and BRCA2 genes
(Bernard-Gallon et al., 2002), which are implicated in inherited
predisposition to BC, showing the presence of a possible
transcriptional or post-transcriptional regulation of BRCA1 and
BRCA2 after omega-3 PUFAs treatment in breast tumor cells
(Bernard-Gallon et al., 2002; Shiovitz and Korde, 2015).
Omega-3 fatty acids are incorporated into phospholipids
of cell membranes during both reticulocyte maturation and
through plasma exchange, making erythrocytes an accurate
indicator of dietary fatty acid intake. The omega-3 index
measures the percentage of the long-chained omega-3 fatty acids,
eicosapentaenoic acid (EPA) and DHA, to total erythrocyte
membranes fatty acids (Harris, 2008).
In this light, we aimed at assessing the ability of DHA
incorporation in RBC membranes, expressed as omega-3 index,
in BC patients and in healthy controls and the potential
differences in the DHA incorporation ability, and at determining
whether the incorporation of DHA could differ in BC patients
with a family history of breast malignancy, either positive or
not for BRCA1/BRCA2 gene mutation. We secondarily verified
a possible association between omega-3 PUFAs levels in RBC
membranes and the inflammatory status.
MATERIALS AND METHODS
This was a spontaneous, single-center, controlled study
performed on patients from the Department of Surgical Sciences,
Sapienza—University of Rome, Italy. After approval of the
local Ethics Committee and after obtaining written informed
consent from each participant, women with diagnosis of BC
and healthy women with no personal and no family history of
BC were recruited. All procedures were in accordance with the
ethical standards of the Helsinki Declaration issued in 1975
and later amendments. Exclusion criteria were: self-reported
consumption of omega-3 PUFAs supplements and omega-3
PUFAs supplemented foods in the previous 6 months.
The sample size was determined based on a previous study
conducted in BC patients observing changes of DHA levels before
and after DHA oral supplementation (Bougnoux et al., 2009).
Participants
We recorded participant’s demographic and anthropometric
characteristics (age, weight, height, body mass index—BMI)
and serum nutritional and metabolic biomarkers, including
cholesterol, low density lipoprotein (LDL), high-density
lipoprotein (HDL), triglycerides. Histological diagnosis, tumor
staging, and a detailed medical history were collected. Based
on the familiar and past medical history, the participants were
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divided in: patients with no family history of breast malignancy—
sporadic (S) group, patients with BC familial history, but
negative for BRCA1 or BRCA2 gene mutation—familiar (F)
group, patients with documented BRCA1 or BRCA2 gene
mutation—mutated (M) group, healthy subjects—control (C)
group matched for age and BMI. Participants were interviewed
regarding the presence of body weight change over the prior 6
months, and for the presence of comorbidities such as diabetes,
hypercholesterolemia, and hypertriglyceridemia. Questionnaire
on participant’s self-reported dietary habits was administered. It
included questions on the habitual consumption of seafood in
the diet, focusing on portion size (i.e., at least a seafood portion
of 80 g) and frequency (once a month/once a week/more than
once a week), as previously validated (Dahl et al., 2011). Based on
the answers given, participants were divided into 2 groups: those
who self-reported eating seafood in the diet once per month or
less than once per month (“low seafood consumer”), and those
who self-reported consuming seafood once per week or more
than once per week (“good seafood consumer”).
Intervention
DHA in the form of algal oil syrup (from Schizochytrium sp.)
containing DHA at 10% (strawberry-flavored Richoil R© syrup,
DMF, Italy) was administered in patients and controls. The
product was provided free of charge by the manufacturer.
Each participant took 10ml of the syrup twice per day for
10 consecutive days, corresponding to 2 g of DHA per day. A
standard normo-balanced diet was prescribed during the same
days, as well as to maintain the usual physical activity level. The
participants were supplied with reference telephone number to
contact for ensuring compliance and to discuss any difficulties
during intervention period.
Blood Sample Collection
Blood samples were collected at baseline (T0), and after DHA
supplementation (after 10 days, T1). Whole blood samples were
collected on overnight fasting by vein puncture in serum tubes
and in ethylenediaminetetraacetic acid (EDTA) tubes, which
were kept into ice and centrifuged at 3,000 rpm for 10min at
+4◦C. After removing the plasma and, carefully, the buffy coat,
the RBC aliquots were stored at−80◦C and then analyzed.
RBC Fatty Acid Assay
RBC fatty acids composition was analyzed by gas
chromatography—flame ionization detection (GC-FID; GC
6850 Agilent Technologies, Santa Clara, CA, USA), as previously
described (Mazzucco et al., 2010), in the Laboratory of the
University of Trieste, Italy. Laboratory personnel were unaware
of the clinical status of the participants (i.e., BC patients or
controls, type of intervention, dietary habits). Specific fatty acids
standards were used to identify fatty acid methyl esters (FAME)
by retention times in erythrocyte samples. Area-under-the-curve
of each selected peak was determined by highly standardized
hand integration performed using commercial software (HP
Chem station; Agilent Technologies, Santa Clara, CA, USA).
RBC membrane level of each fatty acid was expressed as
percent ratio between area-under-the-curve of each selected
FAME peak and the sum of all measured FAME peaks.
Omega 3 index was calculated as sum of the DHA + EPA
in erythrocyte membranes, indicating a percentage of total
erythrocyte fatty acids.
Serum Cytokines Analysis
Cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-
alpha levels were measured in duplicate by commercially
available ELISA kits (Abcam, Cambridge, U.K.) on the blood
samples collected at T0 and T1.
Statistical Analyses
Patient’s characteristics were described using mean ± standard
deviation (SD) for continuous normally distributed variables,
including DHA levels and omega-3 index overall and separately
by group, and percent for dichotomous variables. Not-normally
distributed variables were described using median (25th, 75th
percentiles). Interactions between treatment and participant
characteristics (age, BMI, body weight change) were tested to
identify inter-individual differences in omega-3 index response
to treatment.
One-sample t-tests were used to test for overall change
from T0 to T1. Pearson’s correlation was used to analyze
the association between inflammatory markers and DHA
and omega-3 index, at baseline and after supplementation.
Categorical variables were utilized using proportions by χ2
test. Multivariable regression analysis, adjusting for patient
characteristics (i.e., age, BMI, comorbidity, inflammation,
BC presentation, seafood consumption), was performed to
predict DHA and omega-3 index changes before and after
supplementation. Adjusted P < 0.05 was considered significant.
All statistical analyses were performed in R v. 3.0.2.
RESULTS
Participant’s Characteristics
A total of 45 women were enrolled, including patients and
controls. Two subjects withdrew from the study between T0 and
T1, because no longer interested in the study (1 patient in M
group and 1 healthy control). Forty-three participants, 33 BC
patients and 10 healthy women (C group) completed the study.
Breast cancer patients were distributed as follows: 10 patients in
S group, 12 patients in F group, 11 patients in M group. Baseline
characteristics of the participants are shown in Table 1. Mean age
was 47.3 ± 8.9 years for BC patients and 48.3 ± 5.66 years for
group C.
DHA Levels and Omega-3 Index in RBC
Membranes at Baseline and after
Supplementation and the Role of
Inflammation
At baseline, no significant differences were observed in DHA
levels and omega-3 index between BC patients and controls,
neither between each group of BC patients (S, F, M group).
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TABLE 1 | Participants’ characteristics.
All participants N = 43 BC patients
N = 33, Mean ±
SD*
Controls N = 10,
Mean ± SD*
Age, years 47.33 ± 8.88 48.3 ± 5.66
Body weight, kg 63.91 ± 11.84 60.6 ± 7.4
BMI, weight (kg)/height2 (m) 23.93 ± 3.98 23.68 ± 2.93
Glycemia, mg/dl 94.1 ± 9.57 88.72 ± 9.93
Cholesterol, mg/dl 206.8 ± 28.63 217.7 ± 31.77
Comorbidities:
Diabetes mellitus (yes/no) 2/31 0/10
Hyperlipidemia (yes/no) 7/26 1/10
IL-6, pg/ml 2.12 (0.9, 9.08) 4.04 (0.78, 7.85)







*Median (interquartile range) is shown for non-normally distributed variable (IL-6, TNF-
alpha).
BC, breast cancer; BMI, body mass index; IL, interleukin; TNF, tumor necrosis factor.
All the participants took the DHA oral supplementation.
During and after supplementation, the daily doses of oral DHA
were well tolerated with good compliance in all the participants.
After supplementation, DHA levels and omega-3 index
significantly increased in all groups of BC patients and in
the controls (P < 0.001) (Table 2). No differences in DHA
incorporation and omega-3 index were observed between the
three groups of BC patients and between patients and controls,
except for M group showing higher ability of DHA incorporation
when compared to healthy women (C group) (β= 0.30; P= 0.02)
(Table 3).
At baseline, no differences in TNF-alpha and in IL-6 were
documented in the four groups (Table 1), and no correlation was
found between DHA levels or omega-3 index and cytokines levels
at baseline and after supplementation.
Self-Reported Dietary Seafood
Consumption, DHA, and Omega-3 Index
According to the self-reported seafood eating habits, 33
participants resulted as “good seafood consumers,” 25 BC patients
(7 in S, 11 in F, and 7 in M group) and 8 controls. Ten
participants, 8 BC patients (3 in S, 1 in F, and 4 in M group) and
2 controls resulted as “low seafood consumers” (Tables 1, 4). At
baseline “good seafood consumers” showed higher DHA levels
and omega-3 index with respect to “low seafood consumers”
(Table 4) (P = 0.01). After supplementation, we observed a
significant increase in DHA levels and omega-3 index in “good
seafood consumers” (P < 0.001) (Table 4), as well as in “low
seafood consumers” (P = 0.002 and P = 0.006, respectively)
(Table 4). The increase in DHA levels was higher in “low seafood
consumers” with respect to “good seafood consumer” (P< 0.001)
(Table 3). No association was found between the type of BC
presentation and seafood consumption.
TABLE 2 | DHA levels, EPA levels, and omega-3 index in RBC membranes in the
four groups of participants at baseline (T0) and after DHA supplementation (T1).
All participants
(N = 43)
T0, Mean ± SD T1, Mean ± SD P
S GROUP (N = 10)
DHA 6.14 ± 1.21 7.54 ± 0.97 0.002
EPA 0.53 ± 0.23 0.68 ± 0.22 0.014
Omega-3 Index 6.67 ± 1.33 8.21 ± 1.08 0.002
F GROUP (N = 12)
DHA 6.09 ± 1.11 7.35 ± 1.12 0.003
EPA 0.62 ± 0.27 0.77 ± 0.33 0.004
Omega-3 Index 6.71 ± 1.32 8.12 ± 1.35 <0.001
M GROUP (N = 11)
DHA 5.86 ± 1.51 7.4 ± 1.32 <0.001
EPA 0.60 ± 0.34 0.7 ± 0.27 0.018
Omega-3 Index 6.43 ± 1.75 8.1 ± 1.53 <0.001
C GROUP (N = 10)
DHA 6.1 ± 0.88 7.23 ± 0.7 0.006
EPA 0.52 ± 0.11 0.6 ± 0.1 0.004
Omega-3 Index 6.62 ± 0.9 7.0 ± 0.74 0.002
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; RBC, red blood cell; S group,
sporadic group; F group, familiar group; M group, mutated group; C group, controls.
TABLE 3 | Multivariate regression models to predict variation of DHA levels in
RBC membranes between baseline (T0) and after DHA supplementation (T1).
Clinical characteristics Beta coefficient (95% CI) P
TYPE OF BC PRESENTATION
S group vs. C group 0.12 (−0.21, 0.44) 0.47
F group vs. C group 0.21 (−0.13, 0.55) 0.21
M group vs. C group 0.30 (0.05, 0.55) 0.02
DIETARY SEAFOOD HABITS
Good vs. Low seafood consumer −0.49 (−0.68, −0.30) <0.001
DHA, docosahexaenoic acid; RBC, red blood cell; BC, breast cancer; S group, sporadic
group; F group, familiar group; M group, mutated group; C group, controls.
TABLE 4 | DHA levels, EPA levels and omega-3 index in RBC membranes in
“good” and “low seafood consumers” at baseline (T0) and after DHA
supplementation (T1).
All participants (N = 43) T0, Mean ± SD T1, Mean ± SD P
GOOD SEAFOOD CONSUMERS (N = 33)
DHA 6.29 ± 1.10 7.5 ± 1.03 <0.001
EPA 0.61 ± 0.29 0.74 ± 0.26 <0.001
Omega-3 Index 6.9 ± 1.26 8.24 ± 1.19 <0.001
LOW SEAFOOD CONSUMERS (N = 10)
DHA 5.24 ± 1.04 6.97 ± 0.97 0.002
EPA 0.41 ± 0.09 0.52 ± 0.12 0.014
Omega-3 Index 5.64 ± 1.09 7.49 ± 1.05 0.006
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; RBC, red blood cell.
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DISCUSSION
Several studies have addressed the therapeutic effects of omega-
3 PUFAs in cancer showing that omega-3 PUFAs can improve
efficacy and tolerability of chemotherapy (Bougnoux et al., 2009;
Nabavi et al., 2015). There are clinical trials where DHA alone
or combinations of omega-3 PUFAs are being tested for cancer
prevention, support, or therapy (Berquin et al., 2008; Nabavi
et al., 2015). DHA as a treatment strategy is often combined
with chemotherapeutic drugs since DHA most likely enhances
the cytotoxic effects of these drugs (Nabavi et al., 2015).
Our study aimed at verifying the ability of DHA
incorporation in RBC membranes of BC patients after oral
DHA supplementation compared to heathy women. We found
that DHA levels, and omega-3 index had a significant increase
after a short period of supplementation (10 days) in BC patients,
with no difference related to the type of BC presentation, as
well as between patients and controls. Interestingly, we observed
that only M group had significantly higher DHA increase with
respect to control group. Arterburn et al. (2006) found that DHA
supplementation in healthy humans led to a dose-dependent
increase in RBC DHA and plasma phospholipid and contents.
The data available in the literature are mostly centered on the
effect of DHA supplementation during chemo- and radio-
therapy in reducing adverse side effects and in improving
the outcome of chemotherapy, when highly incorporated
(Bougnoux et al., 2009). Also, studies in experimental models
showed that, under DHA-supplemented diet, peroxisome
proliferator-activated receptors β (PPARβ) is a crucial player
capable of regulating different PPAR mRNA expressions,
which downregulate BC cell growth and mammary tumor
growth (Wannous et al., 2013). The possibility of recognizing
in BC patients potential differences in DHA absorption was
previously evaluated (Bougnoux et al., 2009). In fact, in a phase
II trial, metastatic BC patients were categorized in “low or high
incorporator” according to patient’s ability to incorporate oral
DHA supplementation (Bougnoux et al., 2009). Interestingly,
authors documented that DHA “low incorporators” showed
a worse outcome in term of reduced response to therapy and
increased side effects, such as anemia and thrombopaenia
(Bougnoux et al., 2009). In this respect, we were not able to
demonstrate in our study a similar behavior in BC patients. In
particular, we did not identify one or more groups of patients
with this characteristic, possibly because of several factors,
including age (Walker et al., 2014), that might have influenced
the difference in DHA incorporation described in our study and
by Bougnoux et al. (2009).
Studies in BC patients, where DHA was combined with
the chemotherapeutic drugs epirubicine, cyclophosphamide,
and 5-fluorouracil, emphasize that an interindividual uptake,
and incorporation of DHA can alter the treatment response
(Bougnoux et al., 2009) and reduce BC cell proliferation
(Corsetto et al., 2012). Patients were supplemented with DHA
daily during the chemotherapy cycles and were then divided
into high and low incorporating groups based on the DHA
levels in plasma and RBCs. The high incorporating group
was characterized by delayed time to tumor progression and
longer overall survival compared to the low incorporating
group (Bougnoux et al., 2009). This observation is in line with
other studies showing that DHA incorporation differs between
individuals due to dissimilar rates of metabolism, enzymatic
activity, background diet, age, and gender (Arterburn et al., 2006;
Rusca et al., 2009).
The clinical setting in which the patients were previously
treated for a longer duration of time is different from ours. In
fact, BC patients were supplemented during the entire duration of
chemotherapy (Bougnoux et al., 2009). Our patients were not on
chemotherapy and were orally supplemented with DHA to assess
the capacity of incorporation and not to observe effect associated
with anticancer treatments.
Moreover, when we considered in all the participants
the dietary seafood habits, which were considered a reliable
instrument to assess omega-3 fatty acids intake (Dahl et al., 2011),
we found that “good seafood consumers” had higher DHA levels
at baseline with respect to “low seafood consumers,” confirming
the reliability of our questionnaire.
After supplementation “low seafood consumers” showed
higher DHA increase with respect to “good seafood consumers.”
One possible explanation is represented by the fact that “good
seafood consumers” at baseline presented with higher DHA
levels, and possibly, reaching the maximum rate of absorption of
DHA. In this light, our data are in accordance with those obtained
in the study by Bougnoux et al. (2009), where the highest DHA
levels described in “high incorporators” after supplementation
reached values comparable to the ones obtained in our study.
Since DHA is a highly unsaturated PUFA, it is susceptible
to peroxidation and can cause accumulation of a surplus of
reactive oxygen species that cannot be scavenged by the cancer
cells. Addition of anti-oxidants to cells incubated with DHA
diminishes the toxic effects, strengthening this theory (Lindskog
et al., 2006; Gleissman et al., 2010). In our study we did not assess
this specific effect.
Several metabolic derangements are described in BC patients,
mostly represented by insulin-resistance and alterations in lipid
metabolism (Amadou et al., 2013; Molfino et al., 2016). However,
in our cohort of BC patients we did not observe a high prevalence
of diabetes (only 2 patients), and this might have probably
reduced the possibility to observe effect of DHA supplementation
in this clinical setting.
In the recent years, the composition of the cell membrane
fatty acids has been investigated, not only as a factor influencing
the response to treatments, but also as an element influencing
BC prognosis independent of the treatment received (Bougnoux
et al., 2009, 2010; Straka et al., 2015). Therefore, the identification
of different cell membrane composition at baseline, and a
possible variation in DHA incorporation among the different
type of BC presentation, could be useful in clinical setting. In this
light, our data reveal differences only between BRCA mutation
carriers (M group) and controls. In fact, although patients of M
group did not show differences at baseline in terms of DHA levels
and omega-3 index with respect to the other groups, they showed
greater and significant increase of DHA levels and omega-3 index
after supplementation when compared to healthy women.We are
not able to describe a mechanism underlying this behavior and
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we cannot exclude the possibility that reduced basal DHA level
in BRCA mutation carriers might be at least in part determined
by low dietary DHA intake and/or by impaired absorption of
food-derived DHA amount.
BRCA is the major tumor suppressor gene associated with
hereditary predisposition to BC, and the risk of BC is known to
be increased by a lack of BRCA1/2 protein function (Shiovitz and
Korde, 2015). Interestingly enough, an experimental study found
that DHA supplementation significantly reduced the incidence of
BC and led to 60% increase in BRCA1 protein level with respect
to the control group (not supplemented with DHA), indicating
that BRCA1 up-regulation mediated by DHAmight be protective
against the risk to develop BC (Jourdan et al., 2007). Moreover,
Bernard-Gallon et al. observed an increase of BRCA1 and BRCA2
mRNA expressions in DHA-treated BC cell lines, suggesting
the presence of a possible transcriptional or post-transcriptional
regulation of BRCA1 and BRCA2 genes after omega-3 PUFAs
treatment in BC cells (Bernard-Gallon et al., 2002).
Linking BRCA to key nutritional factors, such as omega-3
PUFAs, involved in the incidence rate of BC (Brasky et al., 2010;
Molfino et al., 2016), opens wide perspectives for nutritional
prevention in BC and in possibly modulating inflammatory
status. Recently, Roy et al. documented positive associations
between erythrocyte and breast tissue omega-3 fatty acids, and
suggestive inverse associations between erythrocyte long chain
omega-3 PUFAs and tissue C-reactive protein (CRP) (Roy et al.,
2015).
Although inflammation is a common condition in BC, our
data fail to reveal increased circulating levels of pro-inflammatory
cytokines in BC patients and no modification of IL-6 and TNF-
alpha were obtained after DHA supplementation. This is in line
with recent data available in the literature, demonstrating that
inflammation is more common in obese BC patients (Gershuni
et al., 2017), although we did not asses high-sensitivity CRP,
which might give additional important information. In fact,
our cohort showed a normal average BMI and it did not
differ between BC patients and controls. Moreover, a recent
randomized trial, conducted in healthy young adults daily
supplemented with oral EPA + DHA for 5 months, showed a
marginal decrease in serum TNF-alpha and no change in IL-6
levels (Flock et al., 2014).
Although our study involved a homogeneous population
of BC patients, enrolled in a single cancer unit, all receiving
the same DHA supplementation and the intervention being
conducted only by one medical team, it presents several
limitations. Our cohort of BC patients is small and may
not be representative of larger BC patients’ population. The
small sample size of the groups enrolled might have limited
the possibility of identifying association between patient’s
characteristics, in particular inflammatory status, and basal DHA
and omega-3 index and DHA absorption overtime (during and
after supplementation). Additionally, the dietary assessment tool
utilized to assess seafood intakes, as an estimate of omega-3
PUFAs intake, might not be accurate, because it does not include
questions on omega-3 PUFAs intakes from other dietary sources.
In conclusion, our study serves as the basis for development
of larger trial to clarify the clinical impact of different DHA
levels and omega-3 index in BC and, in particular, if DHA
supplementation, performed for a short, as we did, or longer
duration of time, has an impact on robust outcomes and if
different subgroups of patients (i.e., BRCA mutation carriers)
present a different and clinically relevant behavior and to
potentially develop novel therapeutic strategies.
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